title: [Rheumatoid arthritis and ankylosing spondylitis--rheumatologic highlights 2007].
abstract: The use of biological therapy is now firmly established in the management of inflammatory rheumatism. The anti-TNFalpha have rightly become agents of choice over the last 10 years, and the recent literature reminds us of their places and indications in ankylosing spondylitis. However, not all patients respond, and the availability of new treatments is certainly a welcome addition. Abatacept is a new treatment for rheumatoid arthritis with an innovative mode of action. It appears effective and safe, and some data as well as practical aspects on its use are presented. Nevertheless, we must still learn to integrate it into our therapeutic strategies, as we are presently doing with rituximab.
authors.affiliation: Service de rhumatologie, médecine physique et réhabilitation, Hôpital Nestlé, CHUV, 1011 Lausanne. jean.dudler@chuv.ch
authors.forename: J
authors.initials: J
authors.lastname: Dudler
authors.forename: B
authors.initials: B
authors.lastname: Aubry-Rozier
mesh_terms: D000069594:Abatacept; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D013167:Spondylitis, Ankylosing / Q000188:drug therapy
chemical_list: D018501:Antirheumatic Agents; D018796:Immunoconjugates; D000069594:Abatacept